Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Use of composite outcomes facilitate core outcome set uptake in rheumatoid arthritis trials

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. How do people with rheumatoid arthritis experience participation in a smoking cessation trial: a qualitative study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Adherence to Treat-to-Target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Dominique Baeten
  • Mikkel Østergaard
  • James Cheng-Chung Wei
  • Joachim Sieper
  • Pentti Järvinen
  • Lai-Shan Tam
  • Carlo Salvarani
  • Tae-Hwan Kim
  • Alan Solinger
  • Yakov Datsenko
  • Chandrasena Pamulapati
  • Sudha Visvanathan
  • David B Hall
  • Stella Aslanyan
  • Paul Scholl
  • Steven J Padula
View graph of relations

OBJECTIVES: To evaluate the efficacy and safety of risankizumab, a humanised monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), in patients with active ankylosing spondylitis (AS).

METHODS: A total of 159 patients with biological-naïve AS, with active disease (Bath Ankylosing Spondylitis Disease Activity Index score of ≥4), were randomised (1:1:1:1) to risankizumab (18 mg single dose, 90 mg or 180 mg at day 1 and weeks 8, 16 and 24) or placebo over a 24-week blinded period. The primary outcome was a 40% improvement in Assessment in Spondylo Arthritis International Society (ASAS40) at week 12. Safety was assessed in patients who received at least one dose of study drug.

RESULTS: At week 12, ASAS40 response rates were 25.5%, 20.5% and 15.0% in the 18 mg, 90 mg and 180 mg risankizumab groups, respectively, compared with 17.5% in the placebo group. The estimated difference in proportion between the 180 mg risankizumab and placebo groups (primary endpoint) was -2.5% (95% CI -21.8 to 17.0; p=0.42). Rates of adverse events were similar in all treatment groups.

CONCLUSIONS: Treatment with risankizumab did not meet the study primary endpoint and showed no evidence of clinically meaningful improvements compared with placebo in patients with active AS, suggesting that IL-23 may not be a relevant driver of disease pathogenesis and symptoms in AS.


Original languageEnglish
JournalAnnals of the Rheumatic Diseases
Issue number9
Pages (from-to)1295-1302
Number of pages8
Publication statusPublished - Sep 2018

Bibliographical note


ID: 56069106